A Review of Transfusion Practice Before, during and after hematopoieti porgenitor cell transplantation
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.
Biol. Blood Marrow Transplant., Nov (2012)
Autologous blood cell transplantation versus HLA-identical siblingtransplantation for acute myeloid leukemia in first complete remission:a registry study from the Center for International Blood and MarrowTransplantation Research.
Haematologica., Sep (2012)
Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research.
Leukemia., May;26(5):1091-7 (2012)
Allogeneic transplant physician and center capacity in the United States.
Biol. Blood Marrow Transplant., Jul;17(7):956-61 (2011)
Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.
Clin Lymphoma Myeloma Leuk., Dec;10(6):458-63 (2010)
One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.
Biol. Blood Marrow Transplant., May;17(5):640-8 (2011)
The National Marrow Donor Program's symposium on patient advocacy in cellular transplantation therapy: addressing barriers to hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Feb;16(2):147-56 (2010)
Response to Letter from Demetrios S. Theodoropoulos, MD, DSc.
Biol. Blood Marrow Transplant., Apr;16(4):561-2 (2010)
Impending challenges in the hematopoietic stem cell transplantation physician workforce.
Biol. Blood Marrow Transplant., Dec;15(12):1493-501 (2009)
A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.
Blood., Oct;112(8):3036-47 (2008)
Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation.
Transfusion., Jan;48(1):163-8 (2008)
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Cancer., Jun;106(11):2327-36 (2006)
ABO blood group barrier in allogeneic bone marrow transplantation revisited.
Biol. Blood Marrow Transplant., Dec;11(12):1006-13 (2005)
The new apheresis and blood and marrow transplantation-related current procedural terminology codes for payment of apheresis and blood and marrow transplantation services.
Biol. Blood Marrow Transplant., Nov;11(11):871-80 (2005)
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Biol. Blood Marrow Transplant., Nov;10(11):794-804 (2004)
Blood and marrow transplantation compensation: perspective in payer and provider relations.
Biol. Blood Marrow Transplant., Jul;10(7):427-32 (2004)
Images in cardiovascular medicine. Constrictive pericarditis in a patient with relapsed acute myelogenous leukemia after allogeneic bone marrow transplantation.
Circulation., Mar;109(9):e146-9 (2004)
Discontinuation of immunosuppression for prevention of kidney graft rejection after receiving a bone marrow transplant from the same HLA identical sibling donor.
Am. J. Hematol., Dec;71(4):311-3 (2002)
Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy.
Bone Marrow Transplant., May;29(10):861-6 (2002)